Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer

Inclusion Criteria:

* Provided signed written informed consent.
* Men and woman age \> 18 years
* Histologically confirmed R0 OR R1 resected ductal adenocarcinoma of the pancreas
* Life expectancy \>12 weeks
* Patients with performance status of ECOG ≤ 2
* Patients without metastasis

Exclusion Criteria:

* Women of child bearing potential (WOCP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and follow-up to 4 weeks after the study.
* Women who are pregnant or breastfeeding.
* Women with a positive pregnancy test on enrollment or prior to study drug administration.
* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for \> 5 years will be allowed to enter the trial).
* Inadequate hematologic function defined by an absolute neutrophils count (ANC) \< 1,500/mm³, a platelet count \< 100,000/mm³ and a hemoglobin \< 9 g/dL.
* Inadequate hepatic function defined by the upper limit of normal (ULN), AST and ALT levels \> 5 times the ULN.
* Serum bilirubin \> 1.5 times the ULN.
* Inadequate renal function defined by a serum creatinine \> 1.5 times the ULN.
* Prior cetuximab or other therapy that targets the EGF pathway.
* Prior antibody therapy.
* Any known allergic reaction against cetuximab.
* Any concurrent chronic systemic immune therapy, radiation therapy, hormonal therapy (except for physiological replacement), or any other investigational agents.
* HIV infection.
* Having participated in another clinical trial in the preceding 30 days.